Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
LQDA shares dropped 36.3% to $8.98 pre-market. FDA granted tentative approval for YUTREPIA inhalation powder. S&P 500 futures gained around 0.1% this morning.
- LQDA shares dropped 36.3% to $8.98 pre-market.
- FDA granted tentative approval for YUTREPIA inhalation powder.
- S&P 500 futures gained around 0.1% this morning.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.